China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma: Zai Lab | 启明创投

投资企业新闻

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma: Zai Lab

2020/05/15 | businesswire

Hyperlink: https://www.businesswire.com/news/home/20200513005458/en/China-NMPA-Approves-Optune%C2%AE-Treatment-Newly-Diagnosed